Hirasen Kamban, Fox Matthew P, Hendrickson Cheryl J, Sineke Tembeka, Onoya Dorina
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
Ther Clin Risk Manag. 2020 Mar 4;16:169-180. doi: 10.2147/TCRM.S227290. eCollection 2020.
Officially rolled out on 01 September 2016, South Africa's Universal Test and Treat (UTT) policy calls for first-line antiretroviral treatment (ART) initiation among all known HIV-positive patients, irrespective of CD4 cell count. We evaluate treatment outcomes of patients initiated on first-line ART directly before and after the implementation of UTT.
We analysed prospectively collected clinical cohort data among ART-naïve adult patients within two HIV clinics in Johannesburg, South Africa. We compare two groups: 1) an unexposed pre-UTT group initiating treatment from 01 December 2014 to 31 May 2015; and 2) an exposed UTT group initiating treatment from 01 December 2016 to 31 May 2017. Primary treatment outcomes included lost to follow-up (LTFU) (>90 days late for the last scheduled visit with no subsequent clinical visit). Cox proportional hazards models were used to estimate the association between pre-UTT vs UTT initiation on LTFU by 12 months.
We included 2410 patients. A total of 1267 (52.6%) patients initiated ART before UTT implementation and 1143 (47.4%) after the change in policy. LTFU (adjusted Hazard Ratio (aHR): 1.51; 95% Confidence Interval (CI): 1.16-1.98) between groups and specifically among those initiating with a CD4 cell count ≤500 cells/mm (aHR: 1.59; 95% CI: 1.21-2.10) was higher among patients initiating ART under UTT.
LTFU under UTT proved higher than that of previous periods. Patients initiating first-line therapy under the treat-all policy may often start treatment in better health, subsequently not perceiving a direct benefit to treatment which may deter patients from consistent engagement in HIV treatment programmes.
南非的“普遍检测与治疗”(UTT)政策于2016年9月1日正式推出,该政策要求对所有已知的HIV阳性患者启动一线抗逆转录病毒治疗(ART),无论其CD4细胞计数如何。我们评估了在UTT实施前后直接开始接受一线ART治疗的患者的治疗结果。
我们分析了在南非约翰内斯堡的两家HIV诊所中前瞻性收集的初治成年患者的临床队列数据。我们比较了两组:1)2014年12月1日至2015年5月31日开始治疗的未暴露于UTT的前UTT组;2)2016年12月1日至2017年5月31日开始治疗的暴露于UTT的UTT组。主要治疗结果包括失访(LTFU)(最后一次预定就诊延迟超过90天且无后续临床就诊)。使用Cox比例风险模型来估计前UTT与UTT启动对12个月时LTFU的关联。
我们纳入了2410名患者。共有1267名(52.6%)患者在UTT实施前开始接受ART治疗,1143名(47.4%)患者在政策变更后开始治疗。在UTT下开始接受ART治疗的患者中,两组之间以及特别是那些CD4细胞计数≤500个细胞/mm³开始治疗的患者中,失访率(调整后的风险比(aHR):1.51;95%置信区间(CI):1.16 - 1.98)更高(aHR:1.59;95%CI:1.21 - 2.10)。
事实证明,UTT下的失访率高于以前时期。在“全面治疗”政策下开始一线治疗的患者可能通常在健康状况较好时开始治疗,随后并未察觉到治疗有直接益处,这可能会阻碍患者持续参与HIV治疗项目。